Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Arthralgia Market Size Changed, over the years?

The market for arthralgia has experienced impressive growth in recent times. It is projected to expand from a value of $5.20 billion in 2024 to an estimated $5.64 billion in 2025, growing at a compound annual growth rate (CAGR) of 8.5%. The historic growth surge in the market can largely be ascribed to the rise in autoimmune diseases, the mounting occurrence of related risk factors, heightened obesity rates, and the escalating incidence of both arthralgia and joint disorders.

How Much Will the Arthralgia Market Be Worth in 2029?

Predictions are strong for a substantial surge in the arthralgia market in the coming years, ballooning up to $7.73 billion by 2029 at a composite annual growth rate (CAGR) of 8.2%. This projected escalation during the predicted period could be credited to several factors including heightened arthralgia awareness, increasing elderly populations, advancements in healthcare facilities, a growing preference for minimally invasive procedures, and a higher frequency of sports-related injuries. Other trends impacting this growth outlook involve the inclusion of digital health strategies, development of new treatments and cell therapies, emerging medical technology, and investments funneled into research and development.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21104&type=smp

Which is the Largest Company in the Arthralgia Market?

Major companies operating in the arthralgia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., UCB S.A., Hikma Pharmaceuticals PLC, Ferring Pharmaceuticals, KD Pharma Group S.A., SI-BONE Inc., Xalud Therapeutics Inc., Incannex Healthcare Limited, Cytonics Corporation, Vitazan Herbs and Vitamins Inc.

What Are the Main Market Drivers in the Arthralgia Industry?

The arthralgia market is predicted to expand owing to the rising occurrences of rheumatoid arthritis. Rheumatoid arthritis is a persistent autoimmune condition which primarily inflicts joints, leading to inflammation, pain, and potential damage. Aging demographics, genetic predisposition, changes in lifestyle, and environmental influences such as smoking and pollution are leading to an increased incidence of rheumatoid arthritis. By sparking chronic inflammation in the joints, rheumatoid arthritis (RA) brings about arthralgia, resulting in pain, stiffness, and incremental damage. As per the data from Arthritis Australia, a non-profit organization based in Australia, the number of arthritis cases in Australia is projected to grow to 5.39 million by 2040 from 4.11 million in 2025. These include an expected rise in osteoarthritis to 3.11 million from 2.35 million and a surge in rheumatoid arthritis to 748,721. Consequently, the surging cases of rheumatoid arthritis are fuelling the growth of the arthralgia market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21104&type=smp

How Is the Arthralgia Market Segments Structured?

The arthralgia market covered in this report is segmented –

1) By Cause: Osteoarthritis, Rheumatoid Arthritis, Gout, Psoriatic Arthritis, Lupus, Injuries, Infections, Other Causes

2) By Treatment Type: Medications, Therapies, Surgical Interventions, Lifestyle And Home Remedies

3) By Route Of Administration: Oral, Injectable, Topical, Transdermal

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospital, Clinics, Homecare Settings, Rehabilitation Centers

Subsegments:

1) By Osteoarthritis: Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, Spine Osteoarthritis, Shoulder Osteoarthritis

2) By Rheumatoid Arthritis: Seropositive Rheumatoid Arthritis, Seronegative Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Early-Onset Rheumatoid Arthritis

3) By Gout: Primary Gout, Secondary Gout, Gouty Arthritis

4) By Psoriatic Arthritis: Symmetric Psoriatic Arthritis, Asymmetric Psoriatic Arthritis, Psoriatic Spondylitis, Distal Interphalangeal Predominant Psoriatic Arthritis

5) By Lupus: Systemic Lupus Erythematosus (SLE), Discoid Lupus Erythematosus, Drug-induced Lupus, Neonatal Lupus

6) By Injuries: Sports-related Injuries, Trauma and Fractures, Sprains and Strains, Tendon or Ligament Damage

7) By Infections: Septic Arthritis, Viral Arthritis, Bacterial Infections, Fungal Infections

8) By Other Causes: Fibromyalgia, Overuse Injuries, Sarcoidosis, Ankylosing Spondylitis, Crystal-induced Arthritis

What Strategic Trends Are Transforming the Arthralgia Market?

Leading firms in the arthralgia market are leveraging their resources to create pioneering therapies such as the RMAT-designated gene therapy. This advanced approach aims to provide extensive pain relief and enhanced joint mobility to patients. RMAT-designated gene therapy is a unique treatment that has gained approval from the FDA under the Regenerative Medicine Advanced Therapy (RMAT) designation, thus accelerating the production and evaluation process of new gene therapies for severe and potentially fatal conditions. To illustrate, Pacira BioSciences Inc., a pharmaceutical company based in the US, earned the RMAT designation for its product PCRX-201 (enekinragene inzadenovec) from the U.S. Food and Drug Administration (FDA) in March 2024. This innovative gene therapy treatment used in knee osteoarthritis applies a helper-dependent adenovirus (HDAd) and is structured to generate interleukin-1 receptor antagonists (IL-1Ra). Gaining the FDA’s inaugural RMAT designation for a gene therapy aimed at osteoarthritis has left Pacira highly enthusiastic. This excitement is further fueled by the promising initial clinical results hinting that PCRX-201 could potentially be a groundbreaking treatment for the disease.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/arthralgia-global-market-report

Which Global Regions Offer the Highest Growth in the Arthralgia Market?

North America was the largest region in the arthralgia market in 2024. The regions covered in the arthralgia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21104

This Report Delivers Insight On:

1. How big is the arthralgia market, and how is it changing globally?

2. Who are the major companies in the arthralgia market, and how are they performing?

3. What are the key opportunities and risks in the arthralgia market right now?

4. Which products or customer segments are growing the most in the arthralgia market?

5. What factors are helping or slowing down the growth of the arthralgia market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model